-
Seattle Genetics (SGEN) PT Raised to $191 at RBC Capital
-
Seattle Genetics (SGEN) PT Raised to $109 at RBC Capital
-
Pre-Open 10/21: (MDR) (OPK) (FSCT) Higher (KMT) (IPHS) (BA) Lower (more...)
-
Seattle Genetics Announces Completion of Public Offering of Common Stock and Exercise in Full of Underwriters' Option to Purchase Additional Shares
-
Seattle Genetics (SGEN) Prices 7.14M Share Offering at $70/Sh
-
Seattle Genetics Announces Pricing of Public Offering of Common Stock
-
Seattle Genetics (SGEN) PT Raised to $80 at RBC Capital
-
Seattle Genetics to Present at RBC Capital Markets 2019 Global Healthcare Conference
-
Seattle Genetics (SGEN) PT Lowered to $79 at RBC Capital
-
Seattle Genetics (SGEN) PT Raised to $90 at RBC Capital; KEYNOTE-204 Delay Removes Overhang
-
Seattle Genetics (SGEN) PT Raised to $89 at RBC Capital
-
RBC Capital Reiterates Outperform Rating on Seattle Genetics (SGEN); KN-204 Data a 'Non-Event'
-
Seattle Genetics (SGEN) PT Lowered to $92 at RBC Capital
-
Seattle Genetics (SGEN) PT Raised to $98 at RBC Capital
-
Seattle Genetics (SGEN) PT Raised to $73 at RBC Capital
-
Pre-Open Movers 01/31: (CASC) (SFLY) (KNX) Higher; (BLCM) (MGI) (CACC) Lower (more...)
-
RBC Capital Starts Seattle Genetics (SGEN) at Outperform
-
Pfizer boosts cancer drug roster with $14 billion Medivation deal
-
Seattle Genetics Announces Exercise of Over-Allotment Option
-
Seattle Genetics (SGEN) Prices 11.7M Common Stock Offering at $41/Share
-
Seattle Genetics Announces Pricing of Public Offering of Common Stock
-
Pre-Open Stock Movers 2/12: (OC) (CSTE) (TRIP) Higher; (VTUS) (RLOC) (PRGN) Lower (more...)
-
Notable Analyst Rating Changes 11/11: (LSCC) (GNW) (DNDN) Upgraded; (CAG) (BRLI) (FSLR) Downgraded
-
Seattle Genetics (SGEN) To Offer Common Shares
-
Notable Analyst Rating Changes 11/09: DNN, CCJ, SYMC, GHDX Upgraded; AKS, RIMM, CXW, UEC Downgraded
-
Notable Analyst Rating Changes 08/31: GPS, ANF, BMY, UBS Upgraded; HPQ, DGIT, RAX, POT Downgraded
-
RBC Capital Upgrades Seattle Genetics (SGEN) To Outperform